Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 3
2010 3
2011 1
2012 2
2013 6
2014 8
2015 20
2016 20
2017 14
2018 18
2019 26
2020 17
2021 22
2022 18
2023 12
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Chen QY, Guo SS, Luo Y, Qu S, Wu DH, Chen XZ, Chen DP, Qin XT, Lin Q, Jin F, Lin SJ, Yao ZF, Liu W, Maxwell Wang Z, Li BY, Xia M, Xu RH, Tang LQ, Mai HQ. Chen QY, et al. Among authors: guo ss. Oral Oncol. 2024 Apr;151:106723. doi: 10.1016/j.oraloncology.2024.106723. Epub 2024 Feb 22. Oral Oncol. 2024. PMID: 38387261 Clinical Trial.
Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
Yu-Chen, Luo MJ, Liu RP, Jin J, Deng SW, Tang LQ, Li XY, Liu LT, Luo DH, Sun R, Liu SL, Li JB, Liu Q, Wang P, Chen QY, Mai HQ, Guo SS. Yu-Chen, et al. Among authors: guo ss. Radiother Oncol. 2024 Feb;191:110051. doi: 10.1016/j.radonc.2023.110051. Epub 2023 Dec 21. Radiother Oncol. 2024. PMID: 38135184 Clinical Trial.
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study.
Liu T, Dong D, Zhao X, Ou XM, Yi JL, Guan J, Zhang Y, Xiao-Fei L, Xie CM, Luo DH, Sun R, Chen QY, Xing L, Guo SS, Liu LT, Lin DF, Chen YZ, Lin JY, Luo MJ, Yan WB, He ML, Mao MY, Zhu MY, Chen WH, Shen BW, Wang SQ, Li HL, Zhong LZ, Hu CS, Wu DH, Mai HQ, Tian J, Tang LQ. Liu T, et al. Among authors: guo ss. BMC Med. 2023 Nov 27;21(1):464. doi: 10.1186/s12916-023-03164-3. BMC Med. 2023. PMID: 38012705 Free PMC article.
Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
Guo SS, Yang JH, Sun XS, Liu LZ, Yang ZC, Liu LT, Liu SL, Li XY, Lv XF, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Sun R, Yang Q, Liang YJ, Jia GD, Zhao C, Chen QY, Tang LQ, Mai HQ. Guo SS, et al. Eur J Cancer. 2023 Nov;194:113336. doi: 10.1016/j.ejca.2023.113336. Epub 2023 Sep 9. Eur J Cancer. 2023. PMID: 37801967 Clinical Trial.
Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA-IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial.
Luo DH, Li XY, Guo SS, Guo WP, Liu LT, Mo HY, Guo L, Lv XF, Liu LZ, Li JB, Liu Q, Wang P, Sun XS, Liu SL, Chen QY, Tang LQ, Mai HQ. Luo DH, et al. Among authors: guo ss. Lancet Reg Health West Pac. 2023 Aug 31;40:100895. doi: 10.1016/j.lanwpc.2023.100895. eCollection 2023 Nov. Lancet Reg Health West Pac. 2023. PMID: 37691885 Free PMC article.
175 results